Abstract
Beal, M. Flint, and John H. Growdon: CSF Neurotransmitter markers in Alzheimer's disease. Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 1986, 10 (3–5): 259–270. 1. 1. CSF neurotransmitter markers may reflect neurochemlcal alterations in Alzheimer's disease (AD). 2. 2. The best studied neurochemical deficit in AD is that of acetylcholine. 3. 3. Both acetylcholinesterase and butyrlcholinesterase activity have been reported to be reduced in some but not all studies of AD CSF. 4. 4. Studies of monoamine metabolites have also been controversial but most authors have found reduced concentrations of CSF HVA, lesser reductions in HIAA and no change in MHPG. 5. 5. CSF GABA concentrations have been found to be reduced in AD. 6. 6. Studies of CSF neuropeptides in AD have shown reduced concentrations of somatostatin and vasopressin, normal concentrations of vasoactive intestinal polypeptide and either normal or decreased concentrations of beta-endorphin and corticotropin releasing factor. 7. 7. Although no individual CSF neurochemical markers are specific for AD it may be possible to develop a profile of several neurochemlcal markers which will have enhanced specificity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Progress in Neuropsychopharmacology & Biological Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
